Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 8.94% and Operating profit at 10.63% over the last 5 years
2
The company has declared Negative results for the last 6 consecutive quarters
3
With ROE of 15.64%, it has a expensive valuation with a 3.49 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 46,877 Million (Large Cap)
22.00
NA
2.93%
-0.58
15.64%
3.49
Revenue and Profits:
Net Sales:
4,448 Million
(Quarterly Results - Jun 2025)
Net Profit:
494 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.02%
0%
-6.02%
6 Months
-12.82%
0%
-12.82%
1 Year
-18.8%
0%
-18.8%
2 Years
-36.98%
0%
-36.98%
3 Years
-31.49%
0%
-31.49%
4 Years
-9.65%
0%
-9.65%
5 Years
32.68%
0%
32.68%
Beijing Tong RenTang Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.94%
EBIT Growth (5y)
10.63%
EBIT to Interest (avg)
24.22
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
1.13
Tax Ratio
18.65%
Dividend Payout Ratio
89.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
87.20%
ROE (avg)
18.15%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
3.49
EV to EBIT
16.22
EV to EBITDA
11.28
EV to Capital Employed
6.93
EV to Sales
2.10
PEG Ratio
NA
Dividend Yield
2.93%
ROCE (Latest)
42.76%
ROE (Latest)
15.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
4,447.80
5,232.10
-14.99%
Operating Profit (PBDIT) excl Other Income
869.70
1,192.60
-27.08%
Interest
31.70
34.60
-8.38%
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
494.30
840.90
-41.22%
Operating Profit Margin (Excl OI)
135.90%
177.30%
-4.14%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -14.99% vs 10.71% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -41.22% vs 183.42% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
18,442.30
17,692.50
4.24%
Operating Profit (PBDIT) excl Other Income
3,637.40
3,897.30
-6.67%
Interest
153.70
119.70
28.40%
Exceptional Items
49.20
1.20
4,000.00%
Consolidate Net Profit
2,280.30
2,583.20
-11.73%
Operating Profit Margin (Excl OI)
141.80%
165.70%
-2.39%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.24% vs 16.36% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -11.73% vs 17.20% in Dec 2023
About Beijing Tong RenTang Co., Ltd. 
Beijing Tong RenTang Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






